Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC)

Go back to Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb (NYSE: BMY) Delayed: 57.13 +0.23 (0.40%)
Previous Close $56.90    52 Week High $77.12 
Open $57.45    52 Week Low $49.03 
Day High $57.60    P/E 37.10 
Day Low $56.77    EPS $1.54 
Volume 7,839,148       

FOUNDATION MEDICINE (NASDAQ: FMI) Delayed: 137.00 +116.53 (569.27%)
Previous Close $20.47    52 Week High $25.31 
Open $20.47    52 Week Low $13.34 
Day High $20.47    P/E N/A 
Day Low $137.00    EPS $-1.61 
Volume 21,435       

Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) Delayed: 51.65 +0.30 (0.58%)
Previous Close $51.35    52 Week High $35.13 
Open $51.53    52 Week Low $28.10 
Day High $51.94    P/E N/A 
Day Low $51.25    EPS $0.00 
Volume 787,643       

RYDEX INVERSE 2X S&P SELECT SECTOR HEALTH CARE ETF (NYSE: RHO) Delayed: 36.81 --0 (-0%)
Previous Close $36.81    52 Week High $55.52 
Open $22.86    52 Week Low $27.48 
Day High $36.81    P/E N/A 
Day Low $36.81    EPS $0.00 
Volume 107,787       

Brown & Brown, Inc. (NYSE: RO) Delayed: 8.49 +0.55 (6.93%)
Previous Close $7.94    52 Week High $8.59 
Open $7.94    52 Week Low $7.82 
Day High $8.59    P/E 6.53 
Day Low $7.82    EPS $1.30 
Volume 42,732